Opinion of the Transparency Council – active substance lanreotidum

At its meeting on 5 August 2024, the Transparency Council adopted opinion No. 119/2024 on the on the inclusion in reimbursement of medicines containing the active substance lanreotidum in the scope of indications for use or dosage or mode of administration different from those specified in the Summary of Product Characteristics, i.e. hyperinsulinism caused by a cause other than that specified in the SmPC

Publication on the list of opinions on active substances for off-label indications >>